The KLOW Stack is a four-peptide research kit that supplies GHK-Cu, KPV, BPC-157, and TB-500 as four separate vials, 80mg of peptide in total. It has become one of the most searched peptide blends of 2026, and most of what is written about it leans harder on marketing than on facts. This guide covers what is actually in the KLOW stack, why the amounts are uneven, what the peer-reviewed research on each component examines, where the blend stands under US compounding rules after the 2026 FDA changes, and how to read a certificate of analysis for a blend. Every mechanism below is tied to the primary literature, and the regulatory status is current to 2026 rather than the outdated pre-2026 rules. Along the way we keep a clear line between the studies that exist and the claims that get built on top of them.
Key Facts At a Glance
| What it is | A four-peptide research blend in one vial |
| Composition | GHK-Cu 50mg, KPV 10mg, BPC-157 10mg, TB-500 10mg |
| Total | 80mg |
| Ratio | 50/10/10/10 (GHK-Cu is about 62.5% of the mass) |
| Relationship | The GLOW blend plus KPV; contains the Wolverine pair |
| Status | Research use only; not FDA-approved |
What Is in KLOW
KLOW takes the three-peptide GLOW blend and adds KPV. The kit holds four separate vials: GHK-Cu, KPV, BPC-157, and TB-500. The name is an acronym for those components, and the composition tells you far more than the label ever will.
Figure 1: Proportional composition of the KLOW Stack – GHK-Cu carries about 62.5% of the 80mg.
The amounts are uneven, and that is the first thing worth understanding. GHK-Cu makes up 50 of the 80 milligrams, close to five-eighths of the kit. The other three peptides share the remaining 30mg evenly, at 10mg each. A researcher reading the amounts can see at a glance what kind of kit this is: a copper-peptide vial carrying most of the mass, alongside three lower-amount vials, with GHK-Cu doing most of the heavy lifting by quantity.
That composition, and the amounts behind it, is the product. Two kits that both say “KLOW” but pack different milligrams per vial are two different preparations, which is why the numbers below carry more weight than the name on the box.
| Component | Amount | Share of vial |
| GHK-Cu | 50mg | ~62.5% |
| KPV | 10mg | 12.5% |
| BPC-157 | 10mg | 12.5% |
| TB-500 | 10mg | 12.5% |
The Four Components, and What Research Examines
Each peptide in the blend carries its own research literature, and almost all of it is in-vitro or animal work. The descriptions below remain in line with what the studies examine.
GHK-Cu (50mg)
The anchor of the blend, at 50 of its 80 milligrams, is a copper-binding tripeptide: glycyl-L-histidyl-L-lysine, carrying a single divalent copper ion. Its literature is the deepest and oldest of the four. A gene-expression review by Pickart and Margolina reported that GHK influences the activity of roughly a third of human genes, and it is studied for its effect on collagen and extracellular-matrix genes in cultured fibroblast and keratinocyte systems.
It occurs naturally in human plasma, where its concentration declines with age, which is part of why it drew research attention in the first place. Its research value comes from the copper: it holds the metal in a bound form, which lets a study examine copper-dependent signaling without introducing a free metal salt, and that carrier role is a large part of why it takes up most of the vial.
KPV (10mg)
The peptide that turns GLOW into KLOW is the smallest tail of a hormone. KPV is the C-terminal tripeptide of alpha-MSH, Lys-Pro-Val, residues 11 to 13, and it keeps the parent hormone’s melanocortin-linked and NF-kB-pathway signaling without the pigment activity. Work by Dalmasso and colleagues examined it in gut-epithelial cell models, where it is studied for inflammatory-pathway signaling.
What makes it unusual is its route in: it crosses the cell membrane through the PepT1 transporter, reaching the intracellular signaling machinery directly, and that uptake step is the mechanism its research returns to most.
BPC-157 (10mg)
Of the four, BPC-157 has the widest injury-model literature, which is why it carries so much of the attention KLOW attracts. It is a fifteen-amino-acid chain derived from a sequence found in gastric juice. A 2025 systematic review in orthopaedic sports medicine (Vasireddi et al.) covered 36 studies, almost all preclinical, examining it across angiogenesis and cytoprotection models.
The thread running through that work is the growth of new blood vessels, which is the role it plays in the blend: the vascular-signaling half of the repair pair.
TB-500 (10mg)
Where BPC-157 works on vessels, TB-500 works on movement. It is a short synthetic fragment of thymosin beta-4, the actin-binding region of the protein (Ac-LKKTETQ, residues 17 to 23), and its research centers on cell migration, the process by which cells travel toward a site.
That actin-sequestering mechanism is well characterized in the thymosin beta-4 literature. Together with BPC-157 it forms the pairing sold on its own as Wolverine, and inside KLOW it is the second half of that repair core.
Why the Four Are Combined
The logic behind any peptide blend is convergent signaling: the idea that several compounds acting on related pathways can be studied together in one preparation. GHK-Cu and the two repair peptides all relate to tissue-signaling and vascular pathways in their respective literatures, and KPV brings the inflammatory-pathway angle to the group. On paper, the four cover a wide slice of the repair-and-signaling map.
There is a practical research reason too. A kit that packages the four peptides at fixed, research-relevant amounts saves a researcher from sourcing and matching them separately, and everyone working from the same kit starts from the same four quantities, which makes results easier to compare across a group.
The limitation deserves equal billing. A blend can show whether a combined preparation produces an effect in a model, yet it cannot show which component did the work, or whether the four interact in ways none of them shows alone. A mixture always carries that trade-off, and it is the reason blends answer some questions while raising others.
KLOW, GLOW and Wolverine
The three blends are nested, which is the quickest way to keep them straight. Wolverine is the pair at the core, GLOW adds a copper peptide, and KLOW adds an inflammatory-pathway peptide on top of that.
Figure 2: The three blends are nested – each larger blend contains the smaller one.
| Blend | Components | Built from |
| Wolverine | BPC-157 + TB-500 | The repair pair |
| GLOW | BPC-157 + TB-500 + GHK-Cu | Wolverine plus GHK-Cu |
| KLOW | BPC-157 + TB-500 + GHK-Cu + KPV | GLOW plus KPV |
Read from the bottom up, each blend contains the one below it. Wolverine is a subset of GLOW, and GLOW is a subset of KLOW. That nesting is also why the names cluster together in search results, and why buyers mix them up: they are three points on one ladder, separated by a single peptide each step.
What the Research on the Components Actually Examines
The research belongs to the individual peptides, and there is very little on the four-peptide combination. Each component has been studied on its own, in the models described above, and that body of work is real and worth reading. What is thin to nonexistent is published research on the specific GHK-Cu/KPV/BPC-157/TB-500 mixture at a 50/10/10/10 ratio.
The published work runs through defined in-vitro and preclinical systems: cultured fibroblasts, keratinocyte lines, dermal papilla cells, and gut-epithelial and animal models, measuring gene expression, cell behavior, and biochemical pathways under set conditions. Results vary with concentration, exposure time, and model, and a finding in one system is not evidence for another.
That difference changes how any “benefit” should be read. Statements about what the blend does are extrapolations, stitched together from single-compound studies, with no direct data on the mixture behind them. Some of those extrapolations may hold up. The catch is that they have not been tested as a combination, so a careful reader treats the component research as the evidence and the four-peptide mixture as an open question.
It is worth being clear about what that does and does not mean. The individual literature is a legitimate foundation, and none of this makes the component peptides less interesting to study. It simply puts the burden of proof in the right place: on the blend, which has not yet earned the claims made for it, rather than on the components, which have earned a genuine research record.
A 2025 systematic review of the BPC-157 literature shows how early this evidence still is. Of 544 articles screened, the authors report that just “36 studies were included (35 preclinical studies, 1 clinical study).” That imbalance is the pattern across all four components: a real single-compound research record, and almost nothing on the combined preparation.
KLOW and US Regulation
In the United States, the four peptides in KLOW are supplied as research chemicals for laboratory use, and none of them is an FDA-approved drug. The blend is not a medicine, and it holds no approval for human or veterinary use. That status shapes how it can be sold: by identity and composition, with no therapeutic claims attached.
The compounding picture moved through 2026, and it is more current than most pages report. In April 2026 the FDA removed several peptides from the 503A Category 2 bulks list, injectable GHK-Cu among them, which took them out of the “significant safety risk” bucket that had restricted compounding. Then in July 2026, the FDA’s Pharmacy Compounding Advisory Committee recommended six peptides for the 503A bulk list, including BPC-157, KPV, and TB-500.
Two things are worth being precise about here.
- That July vote was advisory and non-binding, so FDA leadership still has to decide whether to act on it.
- And removal from Category 2, or a recommendation for the bulk list, is a compounding-eligibility question, a long way short of drug approval.
- So the correct picture for 2026 is that the older “Category 2, restricted” description is out of date, while none of these peptides has become an approved medicine. Anyone citing the pre-2026 rules on a KLOW page is working from a status that no longer applies.
For anyone in sport, one line settles it: BPC-157 and TB-500 are on the WADA Prohibited List, so they are banned in tested competition whatever the compounding status.
Reading the Certificate for a Blend
A blend is harder to verify than a single compound, and the certificate is where that shows. With one peptide, a certificate reports one purity figure against one identity. With four peptides in a vial, a complete certificate has to account for each component and the ratio between them, which is a taller order and one that weaker suppliers quietly skip. When a KLOW listing shows only a single “blend” purity line, that is usually the tell: the seller has tested the mixture as one lump and cannot tell you how much of each peptide the vial actually holds.
The five checks for a blend COA
- Per-component identity. Each of the four peptides is named and confirmed, with its own result, so the certificate covers more than a single “blend” line.
- The stated ratio. The report reflects the 50/10/10/10 composition, so you can see the amounts match the label.
- A batch reference. A lot number ties the certificate to the exact vial in your hand.
- The method. Testing by HPLC for purity and mass spectrometry for identity, so both questions are answered.
- The date. A recent analysis, tied to the batch you received.
Of those five, the per-component identity and the ratio are the two that separate a real blend certificate from a cosmetic one. Any supplier can print a single number; only one that has actually resolved the four peptides can show you that the GHK-Cu really is at 50mg and the other three really are at 10mg each. That is the check most worth insisting on, because it is the one a cutting-corners seller cannot fake without doing the work.
A supplier that publishes a per-component certificate for a blend is doing the harder version of the job, and that willingness is a strong signal on its own. We run a multi-test panel and make the certificate available before purchase; our guide on how to verify a peptide COA walks through each field in detail.
Why the Kit Keeps the Peptides in Separate Vials
Some suppliers sell KLOW as a single pre-mixed vial. This kit keeps the four peptides in four separate vials instead, and for research that difference is worth understanding. A pre-mixed vial commits the four to one solution the moment it is prepared, so a researcher inherits whatever ratio and mixing quality that vial was prepared with. Four separate vials leave those decisions where they belong: each peptide is reconstituted on its own, to its own concentration, on its own schedule.
It also changes what can be verified. Four vials carry four certificates, one per peptide, so identity and purity are confirmed compound by compound. A single pre-mixed vial can only be characterized as a mixture, which is far harder to resolve into per-component numbers, and the per-component number is exactly what a researcher needs to trust the material.
Storage is simple: each vial is kept cold, at 2 to 8 degrees Celsius, and the lyophilized powder travels better than any reconstituted solution. Handled that way, every vial holds its stated amount until the researcher decides to use it.
What KLOW Is Not
A few clarifications save a lot of confusion:
- Not an approved medicine. No component is FDA-approved, and the blend treats no condition. It is a research preparation.
- Not a branded formulation. KLOW is an acronym for its four peptides, so the name describes the contents. Different suppliers offer the same four-peptide blend under it.
- Not a substitute for single-compound work. A researcher who needs to know which peptide produced an effect reaches for the individual compounds, because a blend cannot separate them.
Getting these straight is most of what stands between an accurate understanding of KLOW and the marketing version of it.
Dosing and Administration
We do not publish dosing or administration guidance for KLOW, and that is a deliberate choice. These are research compounds, and concentrations, schedules, and routes belong in the primary literature and in a researcher’s own protocol.
A product guide is the wrong place for any of that, and anyone handing out a KLOW dosage has stepped past what a research supplier should do. If you are designing an experiment, the source material for those decisions is the published work on each component.
How It Is Supplied
The KLOW Stack is supplied as a kit of four separate lyophilized vials, GHK-Cu 50mg, KPV 10mg, BPC-157 10mg, and TB-500 10mg, dispatched together in a kit and to be stored at 2 to 8 degrees Celsius. Keeping the four peptides in separate vials is what lets each one carry its own purity and identity result, and it leaves the researcher in control of how and when each is prepared.
A note about the GHK-Cu vial: once prepared, it typically takes on a faint blue tint, which comes from the bound copper and is expected of a copper peptide. The certificate, not the color, is what confirms the contents, but the tint is a normal characteristic worth recognizing rather than a sign that anything is wrong.
Frequently Asked Questions
What is in the KLOW Stack?
The KLOW Stack is a four-vial kit: GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg), and TB-500 (10mg), 80mg of peptide in total. It is the three-peptide GLOW kit with KPV added, and the name is an acronym for its components.
What does KLOW peptide do?
Each component is studied separately in laboratory research: GHK-Cu in collagen and matrix-gene work, KPV in inflammatory-pathway signaling, BPC-157 in angiogenesis models, and TB-500 in cell-migration research. The four-peptide combination itself has little direct study, so claims about the blend are extrapolated from single-compound data.
What is the difference between KLOW and GLOW?
GLOW is a three-peptide kit of GHK-Cu, BPC-157, and TB-500. KLOW is the same three with KPV added, bringing the kit to four vials and 80mg in total. The added KPV is the C-terminal fragment of alpha-MSH, studied for inflammatory-pathway signaling.
What is the difference between KLOW and Wolverine?
Wolverine is the two-peptide pair of BPC-157 and TB-500. KLOW contains that pair plus GHK-Cu and KPV, so Wolverine is the repair core inside the larger KLOW stack. KLOW totals 80mg; Wolverine is the smaller preparation.
Is KLOW a brand name?
No, KLOW is an acronym describing the four peptides in the kit, so it names a composition. Different suppliers offer the same four-vial kit under the KLOW name, which is why the contents are more important than the label.
Why is the ratio 50/10/10/10 and not even?
GHK-Cu is included at 50mg because it is the copper-peptide anchor of the blend and carries most of its mass. The other three peptides come in at 10mg each. The uneven amounts make GHK-Cu about 62.5% of the vial.
Is the KLOW Stack legal in the US?
The four peptides are supplied as research chemicals for laboratory use, and none is an FDA-approved drug. In 2026 the FDA removed injectable GHK-Cu from the 503A Category 2 list, and an advisory committee recommended BPC-157, KPV, and TB-500 for the compounding bulk list, though that recommendation is non-binding.
What dose of KLOW should be used?
We do not provide dosing for KLOW. These are research compounds, and concentration and administration decisions belong in the primary literature and a researcher’s protocol. A product guide is the wrong place to publish a dose.
Can you buy the KLOW components separately?
Yes, GHK-Cu, KPV, BPC-157, and TB-500 are each sold individually, which is the right choice when a study needs to isolate one mechanism or use only one of the four. The blend suits work that calls for a fixed four-peptide composition; single vials suit work that needs to know which peptide did what.
How should a KLOW blend be stored?
As a lyophilized powder it is kept cold, at 2 to 8 degrees Celsius, which holds the four-peptide composition stable. The freeze-dried format is more robust in transit than a prepared solution, and keeping the vial sealed and cold until use preserves the 50/10/10/10 ratio.
Related Reading
- GHK-Cu
- KPV
- GLOW Stack
- Wolverine Stack
- How to Verify a Peptide COA
Disclaimer
The KLOW Stack and its components are supplied for laboratory research use only, by qualified researchers aged 18 or over. They are not FDA-approved, are not medicines, and are not for human or veterinary use. This article is educational, cites preclinical research for context, and does not provide medical advice or dosing guidance. Sources: Pickart & Margolina (2018), Dalmasso et al. (KPV), Vasireddi et al. (2025), thymosin beta-4/actin literature, FDA 503A bulk substances list, WADA Prohibited List.
How to Verify a Peptide COA Is Real (and Spot a Faked One)
A certificate of analysis is supposed to be your proof that a research peptide is what the label claims. It only works…
Read article
Third-Party vs In-House Peptide Testing: What’s the Difference & Which to Trust (2026)
When a vendor says its research peptide is 99% pure, the number is only half the story. The other half is who…
Read article
How to Read a Peptide COA and Evaluate Research Peptide Quality (US Lab Buyer’s Guide)
To read a peptide Certificate of Analysis (COA), find the batch or lot number on the document, confirm who ran the testing,…
Read articleResearch-grade peptides
99%+ purity. Verified every batch.
Identity and purity tested on every batch by third-party labs, Janoshik Analytical and US-based laboratories. Shipped same day from California.
Shop all peptides